Above the specified price limit, Hong Kong public offering received 3165.1 times oversubscription.

date
22:03 17/10/2025
avatar
GMT Eight
HaiXi New Medicine (02637) announced the results of its allocation, with the company selling 11.5 million H shares globally, of which the Hong Kong public offering accounted for...
(02637) announces the distribution results. The company globally issued 11.5 million H-shares, with 10% allocated for public sale in Hong Kong and 90% for international sale. The final offering price was HK$86.40 per share, with a net fundraising of approximately HK$940 million through the global sale. Each trading unit consists of 50 H-shares, and it is expected that trading of H-shares will commence at 9:00 am on Monday, October 20, 2025, on the Hong Kong Stock Exchange. The public sale in Hong Kong was oversubscribed by 3165.1 times, while the international sale was oversubscribed by 6.3 times.